Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2901
SI-BONE Inc
SIBN
$810M
| $2.02M | ﹤0.01% |
102,392
+10,598
| +12% | +$184K |
2018 Q4
28 quarters
|
|
2902
National Grid
NGG
$76.5B
| $2.02M | ﹤0.01% |
26,086
+1,944
| +8% | +$146K |
2018 Q3
29 quarters
|
|
2903
Amphastar Pharmaceuticals
AMPH
$1.08B
| $2.02M | ﹤0.01% |
75,319
+8,825
| +13% | +$227K |
2014 Q4
44 quarters
|
|
2904
Tyra Biosciences
TYRA
$1.4B
| $2.01M | ﹤0.01% |
76,309
+19,183
| +34% | +$352K |
2022 Q1
15 quarters
|
|
2905
Camden National
CAC
$966M
| $2.01M | ﹤0.01% |
46,242
+13,903
| +43% | +$560K |
2016 Q3
37 quarters
|
|
2906
NetEase
NTES
$75.1B
| $2M | ﹤0.01% |
14,527
-6,117
| -30% | -$868K |
2013 Q2
50 quarters
|
|
2907
Arvinas
ARVN
$485M
| $2M | ﹤0.01% |
168,407
-1,562
| -0.9% | -$17.1K |
2019 Q1
27 quarters
|
|
2908
Schrodinger
SDGR
$2.27B
| $1.99M | ﹤0.01% |
111,371
+12,364
| +12% | +$234K |
2022 Q1
15 quarters
|
|
|
SION
2909
Sionna Therapeutics
SION
$222M
| $1.98M | ﹤0.01% |
48,172
+30,529
| +173% | +$1.16M |
2025 Q2
2 quarters
|
|
2910
Southern Missouri Bancorp
SMBC
$799M
| $1.98M | ﹤0.01% |
33,412
+4,127
| +14% | +$229K |
2016 Q3
37 quarters
|
|
2911
BrightView Holdings
BV
$952M
| $1.97M | ﹤0.01% |
155,746
+24,049
| +18% | +$305K |
2018 Q2
30 quarters
|
|
2912
CTS Corp
CTS
$1.76B
| $1.97M | ﹤0.01% |
45,946
+3,407
| +8% | +$143K |
2016 Q1
39 quarters
|
|
2913
PUT
Melco Resorts & Entertainment
MLCO
$1.59B
| $1.97M | ﹤0.01% |
260,000
| – | – |
2025 Q3
1 quarter
|
|
2914
CALL
NextDecade
NEXT
$1.72B
| $1.96M | ﹤0.01% |
+372,800
| New | +$2.22M |
2025 Q4
0 quarters
|
|
2915
iShares MSCI Global Silver and Metals Miners ETF
SLVP
$896M
| $1.96M | ﹤0.01% |
+57,325
| New | +$1.69M |
2025 Q4
0 quarters
|
|
2916
Galicia Financial Group
GGAL
$5.76B
| $1.96M | ﹤0.01% |
36,378
+13,778
| +61% | +$644K |
2024 Q2
6 quarters
|
|
2917
AMERISAFE
AMSF
$437M
| $1.96M | ﹤0.01% |
51,042
+5,567
| +12% | +$224K |
2016 Q3
37 quarters
|
|
|
DHC
2918
Diversified Healthcare Trust
DHC
$1.87B
| $1.96M | ﹤0.01% |
404,038
+26,906
| +7% | +$122K |
2022 Q1
15 quarters
|
|
2919
Ingles Markets
IMKTA
$1.65B
| $1.96M | ﹤0.01% |
28,563
-16,671
| -37% | -$1.21M |
2015 Q4
40 quarters
|
|
|
WCC
2920
PUT
WESCO International
WCC
$18.6B
| $1.96M | ﹤0.01% |
+8,000
| New | +$1.96M |
2025 Q4
0 quarters
|
|
2921
Hamilton Insurance Group
HG
$3.37B
| $1.95M | ﹤0.01% |
69,938
+5,299
| +8% | +$138K |
2024 Q1
7 quarters
|
|
2922
Carter's
CRI
$1.16B
| $1.95M | ﹤0.01% |
60,093
+8,819
| +17% | +$275K |
2013 Q2
50 quarters
|
|
|
KW
2923
DELISTED
Kennedy-Wilson Holdings
KW
| $1.95M | ﹤0.01% |
201,427
+1,867
| +0.9% | +$16.7K |
2013 Q2
50 quarters
|
|
2924
Columbia Sportswear
COLM
$2.93B
| $1.94M | ﹤0.01% |
35,293
-13,507
| -28% | -$722K |
2013 Q2
50 quarters
|
|
2925
iShares Core S&P Small-Cap ETF
IJR
$105B
| $1.94M | ﹤0.01% |
16,166
-4,882
| -23% | -$584K |
2020 Q2
22 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.